Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOR-1015 in Advanced Solid Malignancies
NCT03782467Phase 1Completed
- Sponsor
- Alligator Bioscience AB
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ATOR-1015 in solid tumor, sponsored by Alligator Bioscience AB. Primary endpoints: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Vital signs and 3 more. Started Jan 2019; status: completed.
02
Drugs
ATOR-1015
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03782467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782467.